S&P 500
5,921.54
+2.0%
+$118.72
DJI
42,343.65
+1.8%
+$740.58
NASDAQ
19,199.16
+2.5%
+$461.96
Bitcoin
109,617.00
+0.1%
+160.07
AAPL
$200.00
+2.4%
+$4.73
AMZN
$205.78
+2.4%
+$4.79
GOOG
$173.90
+2.5%
+$4.32
META
$641.62
+2.3%
+$14.56
MSFT
$460.09
+2.2%
+$9.91
NVDA
$135.32
+3.1%
+$4.03
TSLA
$361.87
+6.6%
+$22.53

Citius Oncology (NASDAQ: CTOR)
$0.89
(-2.3%)
-$0.02
Price as of May 27, 2025, 10:19 a.m. ET
Citius Oncology Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Citius Oncology Company Info
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
News & Analysis
No articles found.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.